C57BL/6N-Ppargtm1c(KOMP)Wtsi/H

Status

Available to order

EMMA IDEM:10145
International strain nameC57BL/6N-Ppargtm1c(KOMP)Wtsi/H
Alternative nameEPD0395_2_A02
Strain typeTargeted Mutant Strains : Targeted Conditional
Allele/Transgene symbolPpargtm1c(KOMP)Wtsi
Gene/Transgene symbolPparg
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider MRC, Medical Research Council
Provider affiliationMary Lyon Centre at MRC Harwell
Genetic informationThis line originates from KOMP ES clone EPD0395_2_A02, after breeding with a Flp recombinase deleter line to convert the original targeted allele tm1a (knock-out first allele) into a conditional allele tm1c. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • embryonic lethality prior to tooth bud stage / IMPC
  • increased fasting circulating glucose level / IMPC
  • decreased lean body mass / IMPC
  • preweaning lethality, complete penetrance / IMPC
  • increased total body fat amount / IMPC
  • abnormal gait / IMPC
MGI phenotypes (gene matching)
  • abnormal adipose tissue distribution / MGI
  • abnormal bone marrow development / MGI
  • abnormal triglyceride level / MGI
  • hypertension / MGI
  • abnormal heart development / MGI
  • abnormal myocardial fiber morphology / MGI
  • thin ventricular wall / MGI
  • enlarged liver / MGI
  • abnormal hepatocyte morphology / MGI
  • decreased body weight / MGI
  • hyperactivity / MGI
  • hyperlipidemia / MGI
  • increased circulating triglyceride level / MGI
  • increased circulating free fatty acid level / MGI
  • hyperglycemia / MGI
  • abnormal circulating alanine transaminase level / MGI
  • extended life span / MGI
  • decreased embryo size / MGI
  • abnormal placenta morphology / MGI
  • abnormal placenta development / MGI
  • placental labyrinth hypoplasia / MGI
  • abnormal placenta labyrinth morphology / MGI
  • postnatal growth retardation / MGI
  • decreased brown adipose tissue amount / MGI
  • decreased white adipose tissue amount / MGI
  • abnormal humoral immune response / MGI
  • reduced fertility / MGI
  • abnormal glucose homeostasis / MGI
  • increased circulating insulin level / MGI
  • prenatal lethality / MGI
  • premature death / MGI
  • abnormal lipid homeostasis / MGI
  • no abnormal phenotype detected / MGI
  • abnormal myocardial trabeculae morphology / MGI
  • decreased susceptibility to hepatic steatosis / MGI
  • abnormal bone marrow morphology / MGI
  • abnormal B cell physiology / MGI
  • increased IgG level / MGI
  • increased IgM level / MGI
  • hepatic steatosis / MGI
  • decreased circulating triglyceride level / MGI
  • thin myocardium / MGI
  • decreased circulating free fatty acid level / MGI
  • decreased circulating insulin level / MGI
  • abnormal retinal vasculature morphology / MGI
  • increased systemic arterial blood pressure / MGI
  • decreased systemic arterial blood pressure / MGI
  • increased insulin sensitivity / MGI
  • abnormal white adipose tissue morphology / MGI
  • abnormal brown adipose tissue morphology / MGI
  • increased liver weight / MGI
  • no phenotypic analysis / MGI
  • increased susceptibility to induced arthritis / MGI
  • abnormal bone structure / MGI
  • embryonic growth retardation / MGI
  • increased incidence of tumors by chemical induction / MGI
  • abnormal chorionic plate morphology / MGI
  • increased adiponectin level / MGI
  • decreased adiponectin level / MGI
  • increased osteoblast cell number / MGI
  • abnormal trophoblast layer morphology / MGI
  • abnormal trophoblast giant cell morphology / MGI
  • abnormal cell differentiation / MGI
  • increased B cell proliferation / MGI
  • abnormal response to injury / MGI
  • increased circulating cholesterol level / MGI
  • decreased circulating cholesterol level / MGI
  • abnormal pancreatic islet morphology / MGI
  • improved glucose tolerance / MGI
  • impaired glucose tolerance / MGI
  • insulin resistance / MGI
  • abnormal gonadal fat pad morphology / MGI
  • abnormal inguinal fat pad morphology / MGI
  • increased circulating aspartate transaminase level / MGI
  • liver/biliary system phenotype / MGI
  • adipose tissue phenotype / MGI
  • homeostasis/metabolism phenotype / MGI
  • growth/size/body region phenotype / MGI
  • immune system phenotype / MGI
  • reproductive system phenotype / MGI
  • skeleton phenotype / MGI
  • pancreatic islet hyperplasia / MGI
  • increased body temperature / MGI
  • decreased body temperature / MGI
  • increased circulating glucose level / MGI
  • decreased susceptibility to diet-induced obesity / MGI
  • decreased circulating leptin level / MGI
  • increased circulating leptin level / MGI
  • abnormal white adipose tissue physiology / MGI
  • decreased body mass index / MGI
  • increased fat cell size / MGI
  • abnormal epididymal fat pad morphology / MGI
  • abnormal bone ossification / MGI
  • abnormal osteoblast differentiation / MGI
  • leukostasis / MGI
  • increased interferon-gamma secretion / MGI
  • increased interleukin-2 secretion / MGI
  • abnormal fetal cardiomyocyte morphology / MGI
  • abnormal placental labyrinth vasculature morphology / MGI
  • absent subcutaneous adipose tissue / MGI
  • decreased subcutaneous adipose tissue amount / MGI
  • decreased total fat pad weight / MGI
  • pancreas hyperplasia / MGI
  • abnormal fat cell morphology / MGI
  • abnormal brown fat cell morphology / MGI
  • abnormal white fat cell morphology / MGI
  • increased brown fat cell size / MGI
  • decreased brown fat cell lipid droplet size / MGI
  • decreased white fat cell number / MGI
  • abnormal white fat cell size / MGI
  • decreased white fat cell size / MGI
  • decreased brown fat lipid droplet number / MGI
  • abnormal endocrine pancreas morphology / MGI
  • decreased gonadal fat pad weight / MGI
  • decreased inguinal fat pad weight / MGI
  • increased interscapular fat pad weight / MGI
  • decreased retroperitoneal fat pad weight / MGI
  • increased liver triglyceride level / MGI
  • increased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • decreased total body fat amount / MGI
  • thin ventricle myocardium compact layer / MGI
  • thin interventricular septum / MGI
  • increased trabecular bone mass / MGI
  • abnormal circadian temperature homeostasis / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • prenatal lethality, complete penetrance / MGI
  • embryonic lethality, complete penetrance / MGI
  • embryonic lethality during organogenesis, complete penetrance / MGI
  • preweaning lethality, complete penetrance / MGI
  • lipodystrophy / MGI
  • decreased food intake / MGI
  • increased fluid intake / MGI
  • abnormal placenta hemotrichorial membrane morphology / MGI
  • decreased white adipose tissue mass / MGI
  • decreased brown adipose tissue mass / MGI
  • increased adipocyte glucose uptake / MGI
  • decreased muscle cell glucose uptake / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*
  • Tissue - Types of tissue, service fee and delivery time available upon request

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).